Bio-Gene Technology Ltd (BGT) — Capital Reinvestment Ratio

Latest as of June 2022: 0.16x

Bio-Gene Technology Ltd (BGT) has a Capital Reinvestment Ratio of 0.16x as of June 2022, meaning it reinvests 0% of its operating cash flow (AU$43.52K) in capital expenditures (AU$6.84K). See BGT equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.16x
Capex / Operating Cash Flow

Operating Cash Flow

AU$43.52K
AUD

Capital Expenditures

AU$6.84K
AUD

Data as of

Jun 2022
Most recent filing

Bio-Gene Technology Ltd Capital Reinvestment Ratio (2022–2022)

This chart tracks Bio-Gene Technology Ltd's Capital Reinvestment Ratio across 1 annual periods. Check BGT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Bio-Gene Technology Ltd (2022–2022)

Year-by-year Capital Reinvestment Ratio for Bio-Gene Technology Ltd from 2022 to 2022. For live market cap and broader valuation context, see BGT market cap overview.

Year Reinvestment Ratio Operating CF (AUD) Capital Expenditures YoY Change
2022 0.16x AU$43.52K AU$6.84K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow